N@N

KDN, NKTR, CIR, REGN, UEPS, VIMC Are Seasonally Ripe To Go Up In the Next Five Weeks

November 28, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of KAYDON CORP (NYSE:KDN), NEKTAR THERAPEUTICS (NASDAQ:NKTR), CIRCOR INTERNATIONAL INC (NYSE:CIR), REGENERON PHARMACEUTICALS INCORPORATED (NASDAQ:REGN), NET 1 UEPS TECHNOLOGIES INC (NASDAQ:UEPS), VIMICRO INTERNATIONAL CO-ADR (NASDAQ:VIMC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     KDN        KAYDON CORP                         8.43%               85.19% (23 of 27)       Tuesday, December 27th 2011
     NKTR       NEKTAR THERAPEUTICS                 13.97%              81.82% (9 of 11)        Tuesday, December 6th 2011
     CIR        CIRCOR INTERNATIONAL INC            7.99%               100.00% (12 of 12)      Wednesday, December 21st 2011
     REGN       REGENERON PHARMACEUTICALS INCORPORATED     24.36%              81.82% (9 of 11)        Monday, January 9th 2012
     UEPS       NET 1 UEPS TECHNOLOGIES INC         21.71%              88.89% (8 of 9)         Wednesday, December 28th 2011
     VIMC       VIMICRO INTERNATIONAL CO-ADR        13.90%              66.67% (4 of 6)         Friday, December 30th 2011

KAYDON CORP (NYSE:KDN) - Kaydon Corporation designs and manufactures custom engineered and performance-critical products primarily in the United States. The companys Friction Control Products segment offers anti-friction bearings, split roller bearings, and specialty balls used in alternative energy, specialized robotics, medical, aerospace, defense, security, electronics, material handling, construction, and other industrial applications. Its Velocity Control Products segment manufactures and sells industrial shock absorbers, safety shock absorbers, velocity controls, gas springs, and rotary dampers used in specialized robotics, material handling, machine tools, medical, amusement, and other industrial applications. The companys Sealing Products segment provides complex and standard ring and seal products, including engine rings, sealing rings, and shaft seals used in industrial, and aerospace and defense applications. Kaydon also offers filter elements, liquid and gas-phase filtration systems, metal alloys, machine tool components, presses, dies, and benders used in various industrial applications. It also has operations in the United Kingdom, Mexico, Germany, North America, Europe, and Asia. The company was founded in 1941 and is based in Ann Arbor, Michigan.

NEKTAR THERAPEUTICS (NASDAQ:NKTR) - Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The companys product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The companys proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinical trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

CIRCOR INTERNATIONAL INC (NYSE:CIR) - CIRCOR International, Inc. engages in the design, manufacture, and marketing of valves and other engineered products and sub-systems. The company operates in three segments: Energy, Aerospace, and Flow Technologies. The Energy Segment offers flanged-end and threaded-end floating and trunnion ball valves, needle valves, check valves, butterfly valves, forged steel ball valves, gate valves, control valves, relief valves, pressure regulators, pipeline measurement, and pipeline closures for use in oil, gas and chemical processing, and industrial applications. This segment provides its products under the brand names of KF, Contromatics, Pibiviesse, Mallard Control, Hydroseal, Sagebrush, and Pipeline Engineering. The Aerospace segment offers precision valves, control valves, relief valves, solenoid valves, couplers, regulators, switches, DC electric motors, and aerospace landing gears for military and commercial aerospace applications. This segment provides its products under the brand names of Aerodyne Controls, Circle Seal Controls, Loud Engineering, Industria, Atkomatic Valve, Survival Engineering, Motor Technology, Bodet Aero, and Atlas Productions. The Flow Technologies segment offers precision valves, compression tube fittings, control valves, relief valves, butterfly valves, couplers, regulators, strainers, and sampling systems for instrumentation, cryogenic, and steam applications. This segment provides its product under the brand names of Cambridge Fluid Systems, Hale Hamilton, Leslie Controls, Nicholson Steam Trap, GO Regulator, Hoke, CIRCORTech, Spence Engineering, CPC-Cryolab, RTK, Rockwood Swendeman, Spence Strainers, Dopak Sampling Systems, Texas Sampling, and Tomco Quick Couplers. The company offers its products through commissioned representatives and direct sales force. It operates in the United States, Canada, Western Europe, and the Peoples Republic of China. The company was founded in 1999 and is based in Burlington, Massachusetts.

REGENERON PHARMACEUTICALS INCORPORATED (NASDAQ:REGN) - Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The companys commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Rilonacept for the prevention and treatment of gout-related flares; VEGF Trap-Eye for eye diseases using intraocular delivery; and Aflibercept for the treatment of oncology. The companys earlier stage clinical programs REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain; REGN88, an antibody to the interleukin-6 receptor, which is developed in rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4, for the treatment of oncology; REGN727, an antibody to proprotein convertase substilisin/kexin type 9, which is developed for low density lipoprotein cholesterol reduction; and REGN668, an antibody to the interleukin-4 receptor for certain allergic and immune conditions. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

NET 1 UEPS TECHNOLOGIES INC (NASDAQ:UEPS) - Net 1 UEPS Technologies, Inc. provides universal electronic payment system (UEPS) as an alternative payment system for the unbanked and under-banked populations in South Africa. The companys UEPS system uses secure smart cards that operate in real time but offline, which means users of the system can enter into transactions at any time with other card holders in even the remote areas; and can be used for banking, health care management, international money transfers, voting, and identification. The company operates in four segments: Transaction-Based Activities; Smart Card Accounts; Financial Services; and Hardware, Software, and Related Technology Sales. The Transaction-Based Activities segment provides state pension and welfare benefit distribution services to provincial governments and transaction processing for retailers, utilities, and banks. This segment also offers payment of social welfare grants, debit orders, and wages; point of sale spending; distribution of medicine; money transfers; prepayment of utility bills and mobile phone airtime; and transaction fees. The Smart Card Accounts segment provides smart card accounts, which primarily consist of social welfare grant beneficiaries to its card holders. The Financial Services segment facilitates short-term loans and life insurance products to the card holders through the smart card delivery channel. The Hardware, Software, and Related Technology Sales segment offers hardware and software required to implement its UEPS system, as well as develops and provides prism secure transaction technology, solutions, and services. Net 1 UEPS Technologies, Inc. also leases terminals to merchants and provides an automated payment collection service to third parties. It primarily serves financial, retail, telecommunication, utilities, and petroleum sectors. The company was founded in 1989 and is headquartered in Johannesburg, South Africa.

VIMICRO INTERNATIONAL CO-ADR (NASDAQ:VIMC) - Vimicro International Corporation, through its subsidiaries, designs, develops, and markets mixed-signal semiconductor products and system-level solutions for the consumer electronics, communications, and surveillance markets in Mainland China, Taiwan, Japan, Hong Kong, and Korea. It offers mixed-signal multimedia processors for personal computer and embedded notebook cameras, as well as for mobile phones. The company provides system-level solutions that include integrated semiconductors, customizable firmware and software, software development tools, reference designs, and applications support. It also offers video surveillance and security products comprising video capturing, compression, transmission, storage, processing, display, and video analysis products. In addition, the company involves in packaging, testing, and reselling third party image sensors. Its products support a range of standards, platforms, and components to facilitate its customers designs, and their assembly and supply chain management processes. Vimicro International sells its products through direct sales force and distributors to original design manufacturers, original equipment manufacturers, design houses, and module manufacturers. The company was founded in 1999 and is based in Beijing, the Peoples Republic of China.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641